Overview

Efficacy and Safety of Losmapimod in Treating Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD) With Open-Label Extension (OLE)

Status:
Enrolling by invitation
Trial end date:
2025-02-01
Target enrollment:
Participant gender:
Summary
This study is an open-label extension to evaluate the safety and tolerability of long-term dosing of Losmapimod in patients with FSHD1 who participated in the ReDux4 study.
Phase:
Phase 2
Details
Lead Sponsor:
Fulcrum Therapeutics